APA

Milojkovic Kerklaan B., Slater S., Flynn M., Greystoke A., Witteveen P. O., Megui-Roelvink M., de Vos F., Dean E., Reyderman L., Ottesen L., Ranson M., Lolkema M. P. J., Plummer R., Kristeleit R., Evans T. R. J. & Schellens J. H. M. (20171219). A phase I, dose escalation, pharmacodynamic, pharmacokinetic, and food-effect study of α2 integrin inhibitor E7820 in patients with advanced solid tumors. : Investigational new drugs.

Chicago

Milojkovic Kerklaan B, Slater S, Flynn M, Greystoke A, Witteveen P O, Megui-Roelvink M, de Vos F, Dean E, Reyderman L, Ottesen L, Ranson M, Lolkema M P J, Plummer R, Kristeleit R, Evans T R J and Schellens J H M. 20171219. A phase I, dose escalation, pharmacodynamic, pharmacokinetic, and food-effect study of α2 integrin inhibitor E7820 in patients with advanced solid tumors. : Investigational new drugs.

Harvard

Milojkovic Kerklaan B., Slater S., Flynn M., Greystoke A., Witteveen P. O., Megui-Roelvink M., de Vos F., Dean E., Reyderman L., Ottesen L., Ranson M., Lolkema M. P. J., Plummer R., Kristeleit R., Evans T. R. J. and Schellens J. H. M. (20171219). A phase I, dose escalation, pharmacodynamic, pharmacokinetic, and food-effect study of α2 integrin inhibitor E7820 in patients with advanced solid tumors. : Investigational new drugs.

MLA

Milojkovic Kerklaan B, Slater S, Flynn M, Greystoke A, Witteveen P O, Megui-Roelvink M, de Vos F, Dean E, Reyderman L, Ottesen L, Ranson M, Lolkema M P J, Plummer R, Kristeleit R, Evans T R J and Schellens J H M. A phase I, dose escalation, pharmacodynamic, pharmacokinetic, and food-effect study of α2 integrin inhibitor E7820 in patients with advanced solid tumors. : Investigational new drugs. 20171219.